Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence

Journal of Cellular Biochemistry

Volumn 91, Issue 3, 2004, Pages 483-190

  Taplin, Mary Ellen ^a   Balk, Steven P ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor; Androgen independent; Hormone refractory; Prostate cancer; Steroid hormone receptor

Indexed keywords

ANDROGEN RECEPTOR; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE;

CANCER GROWTH; CASTRATION; DISEASE COURSE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE DEPENDENCE; HUMAN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; POINT MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 3843069106     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10653     Document Type: Review

References (57)

1. Bola M, Gonzales D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. 1997. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300.
2. Brinkmann AO, Faber PW, Van Roou CJ, Kuiper GGIM, Ris C, Klaassen P, Van der Korput JAGM, Voorhoust MM, Van Laar JH, Mulder E, Trapman J. 1989. The human androgen receptor: Domain structure, genomic organization, and regulation of expression. J Steroid Biochem 34:307-310.
3. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. 2001. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281.
4. Caskey CT, Pizzuti A, Fu y-H, Fenwick RG, Nelson DL. 1992. Triplet repeat mutations in human disease. Science 256:784-789.
5. Chamberlain NI, Driver ED, Miesfeld RI. 1994. The length and location of the CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22:3181-3186.
6. Choong C, Kemppainen J, Zhou Z, Wilson E. 1996. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol 10:1527-1535.
7. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
8. de Vere White RW, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH. 1997. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 31:1-6.
9. Debes J, Schmidt L, Huang H, Tindall DJ. 2002. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 15:5632-5636.
10. Evans RM. 1988. The steroid and thyroid hormone receptor super family. Science 240:889-895.
11. Faber PW, Kuiper GGIM, Van Rooij HCJ, Van der Korput JAGM, Brinkmann AO, Trapman J. 1989. The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol 61:257-262.
12. Gelmann EP. 2002. Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015.
13. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. 1997. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci 94:3320-3323.
14. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. 1998. Androgen receptor gene mutations database. Nucleic Acids Res 26:234-238.
15. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
16. Griffin JE. 1992. Androgen resistance-the clinical and molecular spectrum. N Engl J Med 326:611-618.
17. Grossmann ME, Huang H, Tindall DJ. 2001. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
18. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. 2003. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22:2466-2477.
19. Hara T, Miyazaki J-I, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. 2003. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153.
20. Heinlein CA, Chang C. 2002. Androgen receptor (AR) coregulators: An overview. Endocr Rev 23:175-200.
21. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, D SP, Grygiel JJ, Sutherland RI. 2001. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 61:423-427.
22. Horoszewicz J, Leong S, Kawinski E, Karr J, Rosenthal H, Ming Chu T, Murphy G. 1983. LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818.
23. Irvine RA, Yu MC, Ross RK, Coetzee GA. 1995. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937-1940.
24. Jemal A, Thomas A, Murray T, et al. 2002. Cancer statistics, 2002. CA Cancer J Clin 52:23-47.
25. Jenster G, Van der Korput HAGM, Vroonhoven CV, van der Kwast TH, Trapman J, Brinkmann AO. 1991. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404.
26. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, Dewolf W, Balk SP, Taplin ME, Bubley GJ. 1998. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 159:149-153.
27. Koivisto P, Kononen J, Palmberg C, Tammela TL, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi O-P. 1997. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319.
28. Krishnan AV, Zhao XY, Swami S, Brive L, Pheel DM, Ely K, Feldman D. 2002. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: Therapeutic implications for androgen-independent prostate cancer. Endocrinology 143:1889-1900.
29. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
30. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. 2000. Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949.
31. Matias P, Donner P, Coelho R. 2000. Structural evidence for ligand specificity in the binding domain of the human androgen receptor: Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171.
32. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. 1999. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788.
33. Miyoshi Y, Uemura H, Fujinami K. 2000. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43:225-232.
34. Morris M, Reuter V, Kelly W, Slovin S, Kenneson K, Verbel D, Osman I, Scher HI. 2002. HER-2 profiling and targeting in prostate cancer. Cancer 15:980-986.
35. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN. 2002. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81:191-201.
36. Palmberg C, Koivisto P, Tammela TI, Kallioniemi O-P, Visakorpi T. 2000. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992-1995.
37. Prins GS. 2000. Molecular biology of the androgen receptor. Mayo Clin Proc 75:S32-S35.
38. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C. 2003. Reducing the agonist activity of antiandrogens by a dominant negative androgen receptor coregularor ARA70 in prostate cancer cells. J Biol Chem 278:19619-19626.
39. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, Van der Kwast TH. 1991. Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 39:927-936.
40. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR, Weinmann R, Einspahr HM. 2001. Crystallographic structures of the ligand binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. PNAS 98:4904-4909.
41. Savarese D, Halabi S, Hars V, Akerley W, Taplin M-E, Godley P, Hussain A, Small EJ. 2001. Phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 19:2509-2516.
42. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. 1997. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J Clin Oncol 15:2928-2938.
43. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. 1994. Microsatellite mutation (CAG24-18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74-80.
44. Shariat S, Andrews B, Rattan M, Wheeler KJ, Slawin K. 2001. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58:1008-1015.
45. Small EJ, Vogelzang NJ. 1997. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 15:382-386.
46. Small EJ, Bok R, Reese D, Sudilovsky D, Frohlich M. 2001. Docetaxel, estramustine, plus transtuzumab in patients with metastatic androgen independent prostate cancer. Semin Oncol 28(4 Suppl 15):71-76.
47. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. 1993. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765.
48. Taplin ME, Bubley GJ, Shuster T, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
49. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
50. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes D, Kantoff PW, Vogelzang NJ, Small EJ. 2003. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and leukemia group B study 9663. J Clin Oncol 21:2673-2678.
51. Tilley WD, Buchanan G, Hickey TE, Bentel JM. 1996. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
52. Ueda T, Bruchovsky N, Sadar M. 2002a. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076-7085.
53. Ueda T, Mawji N, Bruchovsky N, Sadar M. 2002b. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094.
54. Veldscholte JC, Kuiper GGIM, Jenster G, Berrevoets C, Claassen E, Van Rooij HC, Trapman J, Brinkmann AO, Mulder E. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540.
55. Veldscholte JC, Berrevoets CA, Zegers ND, Van der Kwast TH, Grootegoed JA, Mulder E. 1992. Hormone-induced dissociation of the androgen receptor-heat shock protein complex: Use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31:7422-7430.
56. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela TL, Isola J, Kallioniemi O-P. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
57. Wang L, Liu X, Kreis W, Budman D. 1999. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 259:21-28.